Regulation of hepatocyte fate by interferon-γ

Cytokine and Growth Factor Reviews

Volumn 22, Issue 1, 2011, Pages 35-43

  Horras, Christopher J ^a   Lamb, Cheri L ^a   Mitchell, Kristen A ^a  

^a BOISE STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Hepatocyte; IFN ; Liver; Proliferation

Indexed keywords

CASPASE 7; CONCANAVALIN A; FAS LIGAND; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA CONVERTING ENZYME; PROTEIN P21; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; APOPTOSIS; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL FUNCTION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA SYNTHESIS; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; FIBROBLAST; GENE ACTIVATION; HEPATITIS; HUMAN; IMMUNOMODULATION; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER FUNCTION; LIVER REGENERATION; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SHORT SURVEY; SIGNAL TRANSDUCTION; STELLATE CELL; VIRUS LOAD;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; HEPATOCYTES; HUMANS; INTERFERON-GAMMA; LIVER; LIVER DISEASES; LIVER REGENERATION; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL;

EID: 79952250105     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2011.01.001     Document Type: Short Survey

References (143)

1. Billiau A., Matthys P. Interferon-gamma: a historical perspective. Cytokine & Growth Factor Reviews 2009, 20:97-113.
2. Kano A., Watanabe Y., Takeda N., Aizawa S., Akaike T. Analysis of IFN-gamma-induced cell cycle arrest and cell death in hepatocytes. Journal of Biochemistry 1997, 121:677-683.
3. Shinagawa T., Yoshioka K., Kakumu S., Wakita T., Ishikawa T., Itoh Y., et al. Apoptosis in cultured rat hepatocytes: the effects of tumor-necrosis-factor-alpha and interferon-gamma. Journal of Pathology 1991, 165:247-253.
4. Michalopoulos G.K. Liver regeneration after partial hepatectomy critical analysis of mechanistic dilemmas. American Journal of Pathology 2010, 176:2-13.
5. Lalor P.F., Shields P., Grant A.J., Adams D.H. Recruitment of lymphocytes to the human liver. Immunology and Cell Biology 2002, 80:52-64.
6. Valente G., Ozmen L., Novelli F., Geuna M., Palestro G., Forni G., et al. Distribution of interferon-gamma receptor in human tissues. European Journal of Immunology 1992, 22:2403-2412.
7. Lai H.S., Lin W.H., Hsu W.M., Chen C.N., Chang K.J., Lee P.H. Variations in interferon gamma receptor gene expression during liver regeneration after partial hepatectomy in rats. American Surgeon 2009, 75:49-54.
8. Crispe I.N. The liver as a lymphoid organ. Annual Review of Immunology 2009, 27:147-163.
9. Wullaert A., van Loo G., Heyninck K., Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappa B: effects on liver homeostasis and beyond. Endocrine Reviews 2007, 28:365-386.
10. Farrar M.A., Schreiber R.D. The molecular cell biology of interferon-gamma and its receptor. Annual Review of Immunology 1993, 11:571-611.
11. Shuai K., Stark G.R., Kerr I.M., Darnell J.E. A single phosphotyrosine residue of stat91 required for gene activation by interferon-gamma. Science 1993, 261:1744-1746.
12. Wen Z.L., Zhong Z., Darnell J.E. Maximal activation of transcription by stat1 and stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-250.
13. Ihle J.N., Witthuhn B.A., Quelle F.W., Yamamoto K., Thierfelder W., Kreider B., et al. Signaling by the cytokine receptor superfamily - jaks and stats. Trends in Biochemical Sciences 1994, 19:222-227.
14. Sato T., Selleri C., Young N.S., Maciejewski J.P. Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3. Blood 1997, 90:4749-4758.
15. Saha B., Prasanna S.J., Chandrasekar B., Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 2010, 50:1-14.
16. Tamura T., Yanai H., Savitsky D., Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annual Review of Immunology 2008, 26:535-584.
17. Gough D.J., Levy D.E., Johnstone R.W., Clarke C.J. IFN-gamma signaling: does it mean JAK-STAT?. Cytokine & Growth Factor Reviews 2008, 19:383-394.
18. Ramana C.V., Grammatikakis N., Chernov M., Nguyen H., Goh K., Williams B., et al. Regulation of c-myc expression by IFN-gamma through Stat1-dependent and -independent pathways. EMBO Journal 2000, 19:263-272.
19. Gil M.P., Bohn E., O'Guin A.K., Ramana C., Levine B., Stark G., et al. Biologic consequences of Stat1-independent IFN signaling. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:6680-6685.
20. Deb A., Haque S.J., Mogensen T., Silverman R.H., Williams B.R.G. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. Journal of Immunology 2001, 166:6170-6180.
21. Morita M., Watanabe Y., Akaike T. Protective effect of hepatocyte growth-factor on interferon-gamma-induced cytotoxicity in mouse hepatocytes. Hepatology 1995, 21:1585-1593.
22. Kano A., Haruyama T., Akaike T., Watanabe Y. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochemical and Biophysical Research Communications 1999, 257:672-677.
23. Romeo G., Fiorucci G., Chiantore M.V., Percario Z.A., Vannucchi S., Affabris E. IRF-1 as a negative regulator of cell proliferation. Journal of Interferon and Cytokine Research 2002, 22:39-47.
24. Kroger A., Koster M., Schroeder K., Hauser H., Mueller P.P. Activities of IRF-1. Journal of Interferon and Cytokine Research 2002, 22:5-14.
25. Sanceau J., Hiscott J., Delattre O., Wietzerbin J. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 2000, 19:3372-3383.
26. Tamura T., Ishihara M., Lamphier M.S., Tanaka N., Oishi I., Aizawa S., et al. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 1995, 376:596-599.
27. Chow W.A., Fang J.J., Yee J.K. The IFN regulatory factor family participates in regulation of Fas ligand gene expression in T cells. Journal of Immunology 2000, 164:3512-3518.
28. Watanabe Y., Suzuki O., Haruyama T., Akaike T. Interferon-gamma induces reactive oxygen species and endoplasmic reticulum stress at the hepatic apoptosis. Journal of Cellular Biochemistry 2003, 89:244-253.
29. Kanki K., Kawamura T., Watanabe Y. Control of ER stress by a chemical chaperone counteracts apoptotic signals in IFN-gamma-treated murine hepatocytes. Apoptosis 2009, 14:309-319.
30. Melen K., Keskinen P., Lehtonen A., Julkunen I. Interferon-induced gene expression and signaling in human hepatoma cell lines. Journal of Hepatology 2000, 33:764-772.
31. Vadrot N., Legrand A., Nello E., Bringuier A.F., Guillot R., Feldmann G. Inducible nitric oxide synthase (iNOS) activity could be responsible for resistance or sensitivity to IFN gamma-induced apoptosis in several human hepatoma cell lines. Journal of Interferon and Cytokine Research 2006, 26:901-913.
32. Liu J., Saavedra J.E., Lu T., Song J., Clark J., Waalkes M., et al. O-2-Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate protection against d-galactosamine/endotoxin-induced hepatotoxicity in mice: genomic analysis using microarrays. Journal of Pharmacology and Experimental Therapeutics 2002, 300:18-25.
33. Ou J.H., Carlos T.M., Watkins S.C., Saavedra J., Keefer L., Kim Y., et al. Differential effects of nonselective nitric oxide synthase (NOS) and selective inducible NOS inhibition on hepatic necrosis, apoptosis, ICAM-1 expression, and neutrophil accumulation during endotoxemia. Nitric Oxide-Biology and Chemistry 1997, 1:404-416.
34. Rai R.M., Lee F.Y.J., Rosen A., Yang S., Lin H., Koteish A., et al. Impaired liver regeneration in inducible nitric oxide synthase-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:13829-13834.
35. Yagnik G.P., Takahashi Y., Tsoulfas G., Reid K., Murase N., Geller D.A. Blockade of the l-arginine/NO synthase pathway worsens hepatic apoptosis and liver transplant preservation injury. Hepatology 2002, 36:573-581.
36. Gao J.J., Morrison D.C., Parmely T.J., Russell S.W., Murphy W.J. An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide. Journal of Biological Chemistry 1997, 272:1226-1230.
37. Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Sahpiro D., et al. Requirement for transcription factor IRF-1 in no synthase induction in macrophages. Science 1994, 263:1612-1615.
38. Martin E., Nathan C., Xie Q.W. Role of interferon regulatory factor-1 in induction of nitric-oxide synthase. Journal of Experimental Medicine 1994, 180:977-984.
39. Vodovotz Y., Kirn P.K.M., Bagci E.Z., Ermentrout G., Chow C., Bahar I., et al. Inflammatory modulation of hepatocyte apoptosis by nitric oxide: in vivo, in vitro, and in silico studies. Current Molecular Medicine 2004, 4:753-762.
40. Dimmeler S., Haendeler J., Nehls M., Zeiher A.M. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1 beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. Journal of Experimental Medicine 1997, 185:601-607.
41. Kim Y.M., Talanian R.V., Billiar T.R. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. Journal of Biological Chemistry 1997, 272:31138-31148.
42. Li J.R., Billiar T.R., Talanian R.V., Kim Y.M. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochemical and Biophysical Research Communications 1997, 240:419-424.
43. Li J.R., Yang S.F., Billiar T.R. Cyclic nucleotides suppress tumor necrosis factor alpha-mediated apoptosis by inhibiting caspase activation and cytochrome c release in primary hepatocytes via a mechanism independent of Akt activation. Journal of Biological Chemistry 2000, 275:13026-13034.
44. Mannick J.B., Miao X.Q., Stamler J.S. Nitric oxide inhibits Fas-induced apoptosis. Journal of Biological Chemistry 1997, 272:24125-24128.
45. Ogasawara J., Watanabefukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806-809.
46. Leist M., Gantner F., Bohlinger I., Germann P.G., Tiegs C., Wendel A. Murine hepatocyte apoptosis induced in-vitro and in-vivo by TNF-alpha requires transcriptional arrest. Journal of Immunology 1994, 153:1778-1788.
47. Rolfe M., James N.H., Roberts R.A. Tumour necrosis factor alpha (TNF alpha) suppresses apoptosis and induces DNA synthesis in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators?. Carcinogenesis 1997, 18:2277-2280.
48. Huh C., Factor V., Sánchez A., Uchida K., Conner E., Thorgeirsson S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:4477-4482.
49. Ishiki Y., Ohnishi H., Muto Y., Matsumoto K., Nakamura T. Direct evidence that hepatocyte growth-factor is a hepatotrophic factor for liver-regeneration and has a potent antihepatitis effect invivo. Hepatology 1992, 16:1227-1235.
50. McCullough C.T., Tura B.J., Harrison D.J. Growth factor attenuation of IFN gamma-mediated hepatocyte apoptosis requires p21(waf-1). International Journal of Experimental Pathology 2006, 87:275-281.
51. Detjen K.M., Murphy D., Welzel M., Farwig K., Wiedenmann B., Rosewicz S. Downregulation of p21(waf/cip-1) mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-gamma. Experimental Cell Research 2003, 282:78-89.
52. Yang G., Xu Y., Chen X., Hu G. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene 2007, 26:594-603.
53. Sun R., Park O., Horiguchi N., Kulkarni S., Jeong W.I., Sun H.Y., et al. STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice. Hepatology 2006, 44:955-966.
54. Chin Y.E., Kitagawa M., Su W.C.S., You Z.H., Iwamoto Y., Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) mediated by STAT1. Science 1996, 272:719-722.
55. Macleod K.F., Sherry N., Hannon G., Beach D., Tokino T., Kinzler K., et al. P53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes & Development 1995, 9:935-944.
56. Townsend P.A., Scarabelli T.M., Davidson S.M., Knight R.A., Latchman D.S., Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. Journal of Biological Chemistry 2004, 279:5811-5820.
57. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
58. Takami K., Takuwa N., Okazaki H., Kobayashi M., Ohtoshi T., Kawasaki S., et al. Interferon-gamma inhibits hepatocyte growth factor-stimulated cell proliferation of human bronchial epithelial cells upregulation of p27(kip1) cyclin-dependent kinase inhibitor. American Journal of Respiratory Cell and Molecular Biology 2002, 26:231-238.
59. Fausto N., Campbell J.S., Riehle K.J. Liver regeneration. Hepatology 2006, 43:S45-S53.
60. Michalopoulos G.K. Liver regeneration. Journal of Cellular Physiology 2007, 213:286-300.
61. Sun R., Gao B. Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-gamma). Gastroenterology 2004, 127:1525-1539.
62. Habu S., Fukui H., Shimamura K., Kasai M., Nagai Y., Okumura K., et al. In vivo effects of anti-asialo gm1: 1. Reduction of NK activity and enhancement of transplanted tumor-growth in nude-mice. Journal of Immunology 1981, 127:34-38.
63. Tamura F., Masuhara A., Sakaida I., Fukumoto E., Nakamura T., Okita K. FK506 promotes liver regeneration by suppressing natural killer cell activity. Journal of Gastroenterology and Hepatology 1998, 13:703-708.
64. Tanigawa K., Sakaida I., Masuhara M., Hagiya M., Okita K. Augmenter of liver regeneration (ALR) may promote liver regeneration by reducing natural killer (NK) cell activity in human liver diseases. Journal of Gastroenterology 2000, 35:112-119.
65. Vujanovic N.L., Polimeno L., Azzarone A., Francavilla A., Chambers W.H., Starzl T.E., et al. Changes of liver-resident nk cells during liver-regeneration in rats. Journal of Immunology 1995, 154:6324-6338.
66. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappa B by Toll-like receptor 3. Nature 2001, 413:732-738.
67. Dong Z., Zhang J., Sun R., Wei H., Tian Z. Impairment of liver regeneration correlates with activated hepatic NKT cells in HBV transgenic mice. Hepatology 2007, 45:1400-1412.
68. Moon D.B., Lee S.G. Liver transplantation. Gut and Liver 2009, 3:145-165.
69. Issa F., Schiopu A., Wood K.J. Role of T cells in graft rejection and transplantation tolerance. Expert Review of Clinical Immunology 2010, 6:155-169.
70. Roayaie S., Sheiner P.A., Emre S., Guy S., Schwartz M.E., Boros P., et al. Cytokine profiles in early rejection following OKT3 treatment in liver transplant patients. Mediators of Inflammation 2000, 9:141-146.
71. Shen K., Zheng S.S., Park O., Wang H., Sun Z., Gao B. Activation of innate immunity (NK/IFN-gamma) in rat allogeneic liver transplantation: contribution to liver injury and suppression of hepatocyte proliferation. American Journal of Physiology-Gastrointestinal and Liver Physiology 2008, 294:G1070-1077.
72. Tiegs G. Cellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury. Zeitschrift Fur Gastroenterologie 2007, 45:63-70.
73. Hardtke-Wolenski M., Jaeckel E. Mouse models for experimental autoimmune hepatitis: limits and Chances. Digestive Diseases 2010, 28:70-79.
74. Kim K.M., Kim Y.M., Park M., Park K., Chang H.K., Park T.K., et al. A broad-spectrum caspase inhibitor blocks concanavalin A-induced hepatitis in mice. Clinical Immunology 2000, 97:221-233.
75. Kunstle G., Hentze H., Germann P.G., Tiegs G., Meergans T., Wendel A. Concanavalin A hepatotoxicity in mice: tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation. Hepatology 1999, 30:1241-1251.
76. Tagawa Y., Kakuta S., Iwakura Y. Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. European Journal of Immunology 1998, 28:4105-4113.
77. Tiegs G., Hentschel J., Wendel A. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. Journal of Clinical Investigation 1992, 90:196-203.
78. Tiegs G. Experimental hepatitis and role of cytokines. Acta Gastro-Enterologica Belgica 1997, 60:176-179.
79. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:5498-5503.
80. Hong F., Jaruga B., Kim W.H., Radaeva S., El-Assal O.N., Tian Z.G., et al. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. Journal of Clinical Investigation 2002, 110:1503-1513.
81. Ksontini R., Colagiovanni D.B., Josephs M.D., Edwards C.K., Tannahill C.L., Solorzano C.C., et al. Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis. Journal of Immunology 1998, 160:4082-4089.
82. Kusters S., Gantner F., Kunstle G., Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996, 111:462-471.
83. Siebler J., Wirtz S., Klein S., Protschka M., Blessing M., Galle P.R., et al. A key pathogenic role for the STAT1/T-bet signaling pathway in T-cell-mediated liver inflammation. Hepatology 2003, 38:1573-1580.
84. Mizuhara H., Uno M., Seki N., Yamashita M., Yamaoka M., Ogawa T., et al. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology 1996, 23:1608-1615.
85. Nicoletti F., Zaccone P., Xiang M., Magro G., Di Mauro M., Di Marco R., et al. Essential pathogenetic role for interferon (IFN-)gamma in concanavalin A-induced T cell-dependent hepatitis: exacerbation by exogenous IFN-gamma and prevention by IFN-gamma receptor-immunoglobulin fusion protein. Cytokine 2000, 12:315-323.
86. Jaruga B., Hong F., Kim W.H., Gao B. IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. American Journal of Physiology-Gastrointestinal and Liver Physiology 2004, 287:G1044-G1052.
87. Senaldi G., Shaklee C.L., Guo J., Martin L., Boone T., Mak T.W., et al. Protection against the mortality associated with disease models mediated by TNF and IFN-gamma in mice lacking IFN regulatory factor-1. Journal of Immunology 1999, 163:6820-6826.
88. Streetz K., Fregien B., Plumpe J., Korber K., Kubicka S., Sass G., et al. Dissection of the intracellular pathways in hepatocytes suggests a role for Jun kinase and IFN regulatory factor-1 in Con A-induced liver failure. Journal of Immunology 2001, 167:514-523.
89. Grad J.M., Zeng X.R., Boise L.H. Regulation of Bcl-x(L): a little bit of this and a little bit of STAT. Current Opinion in Oncology 2000, 12:543-549.
90. Naka T., Fujimoto M., Kishimoto T. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends in Biochemical Sciences 1999, 24:394-398.
91. Nicola N.A., Nicholson S.E., Metcalf D., Zhang J.G., Baca M., Farley A., et al. Negative regulation of cytokine signaling by the SOCS proteins. Cold Spring Harbor Symposia on Quantitative Biology 1999, 64:397-404.
92. Colletti L.M., Kunkel S.L., Green M., Burdick M., Strieter R.M. Hepatic inflammation following 70% hepatectomy may be related to up-regulation of epithelial neutrophil activating protein-78. Shock 1996, 6:397-402.
93. Colletti L.M., Green M., Burdick M.D., Kunkel S.L., Strieter R.M. Proliferative effects of CXC chemokines in rat hepatocytes in vitro and in vivo. Shock 1998, 10:248-257.
94. Gujral J.S., Liu J., Farhood A., Hinson J.A., Jaeschke H. Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. American Journal of Physiology-Gastrointestinal and Liver Physiology 2004, 286:G499-G507.
95. Park J.W., Gruys M.E., McCormick K., Lee J.K., Subleski J., Wigginton J.M., et al. Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2). Journal of Immunology 2001, 166:3763-3770.
96. Selzner N., Selzner M., Odermatt B., Tian Y.H., Van Rooijen N., Clavien P.A. ICAM-1 triggers liver regeneration through leukocyte recruitment and Kupffer cell-dependent release of TNF-alpha/IL-6 in mice. Gastroenterology 2003, 124:692-700.
97. Guidotti L.G., Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annual Review of Pathology-Mechanisms of Disease 2006, 1:23-61.
98. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annual Review of Immunology 1995, 13:29-60.
99. Shoukry N.H., Cawthon A.G., Walker C.M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annual Review of Microbiology 2004, 58:391-424.
100. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
101. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., Salazar-Mather T.P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annual Review of Immunology 1999, 17:189-220.
102. Bigger C.B., Brasky K.M., Lanford R.E. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. Journal of Virology 2001, 75:7059-7066.
103. Wieland S., Thimme R., Purcell R.H., Chisari F.V. Genomic analysis of the host response to hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:6669-6674.
104. Thimme R., Oldach D., Chang K.M., Steiger C., Ray S.C., Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. Journal of Experimental Medicine 2001, 194:1395-1406.
105. Thimme R., Wieland S., Steiger C., Ghrayeb J., Reimann K.A., Purcell R.H., et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. Journal of Virology 2003, 77:68-76.
106. Nakamoto Y., Guidotti L.G., Pasquetto V., Schreiber R.D., Chisari F.V. Differential target cell sensitivity to CTL-activated death pathways in hepatitis B virus transgenic mice. Journal of Immunology 1997, 158:5692-5697.
107. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annual Review of Immunology 2001, 19:65-91.
108. Frese M., Schwarzle V., Barth K., Krieger N., Lohmann V., Mihm S., et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002, 35:694-703.
109. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:25-36.
110. McClary H., Koch R., Chisari F.V., Guidotti L.G. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. Journal of Virology 2000, 74:2255-2264.
111. Guidotti L.G., McClary H., Loudis J.M., Chisari F.V. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. Journal of Experimental Medicine 2000, 191:1247-1252.
112. Guidotti L.G., Morris A., Mendez H., Koch R., Silverman R.H., Williams B.R.G., et al. Intertlueron-regulated pathways that control hepatitis B virus replication in transgenic mice. Journal of Virology 2002, 76:2617-2621.
113. Steimle V., Siegrist C.A., Mottet A., Lisowskagrospierre B., Mach B. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994, 265:106-109.
114. Zhou F. Molecular mechanisms of IFN-gamma to upregulate MHC class I antigen processing and presentation. International Reviews of Immunology 2009, 28:239-260.
115. Van den Eynde B.J., Morel S. Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome. Current Opinion in Immunology 2001, 13:147-153.
116. Bonecchi R., Bianchi G., Bordignon P.P., D'Ambrosio D., Land R., Borsatti A., et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. Journal of Experimental Medicine 1998, 187:129-134.
117. Kakimi K., Lane T.E., Wieland S., Asensio V.C., Campbell I.L., Chisari F.V., et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. Journal of Experimental Medicine 2001, 194:1755-1766.
118. Prezzi C., Casciaro M.A., Francavilla V., Schiaffella E., Finocchi L., Chircu L.V., et al. Virus-specific CD8+ T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. European Journal of Immunology 2001, 31:894-906.
119. Shields P.L., Morland C.M., Salmon M., Qin S.X., Hubscher S.G., Adams D.H. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. Journal of Immunology 1999, 163:6236-6243.
120. Bataller R., Brenner D.A. Liver fibrosis. Journal of Clinical Investigation 2005, 115:209-218.
121. Dore G.J., Freeman A.J., Law M., Kaldor J.M. Is severe liver disease a common outcome for people with chronic hepatitis C?. Journal of Gastroenterology and Hepatology 2002, 17:423-430.
122. Serfaty L., Chazouilleres O., PoujolRobert A., MorandJoubert L., Dubois C., Chretien Y., et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology 1997, 26:776-779.
123. Benvegnu L.B., Pontisso P., Cavalletto D., Noventa F., Chemello L., Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997, 25:211-215.
124. Sobue S., Nomura T., Ishikawa T., Ito S., Saso K., Ohara H., et al. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. Journal of Gastroenterology 2001, 36:544-551.
125. Bonilla N., Barget N., Andrieu M., Roulot D., Letoumelin P., Grando V., et al. Interferon gamma-secreting HCV-specific CD8+T cells in the liver of patients with chronic C hepatitis: relation to liver fibrosis - ANRS HC EP07 study. Journal of Viral Hepatitis 2006, 13:474-481.
126. Nelson D.R., Marousis C.G., Davis G.L., Rice C.M., Wong J., Houghton M., et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. Journal of Immunology 1997, 158:1473-1481.
127. Baroni G.S., Dambrosio L., Curto P., Casini A., Mancini R., Jezequel A.M., et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996, 23:1189-1199.
128. Rockey D.C., Chung J.J. Interferon-gamma inhibits lipocyte activation and extracellular-matrix messenger RNA expression during experimental liver injury: implications for treatment of hepatic-fibrosis. Journal of Investigative Medicine 1994, 42:660-670.
129. Muir A.J., Sylvestre P.B., Rockey D.C. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. Journal of Viral Hepatitis 2006, 13:322-328.
130. Rockey D.C., Maher J.J., Jarnagin W.R., Gabbiani G., Friedman S.L. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 1992, 16:776-784.
131. Jeong W.I., Park O., Radaeva S., Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 2006, 44:1441-1451.
132. Breitkopf K., Godoy P., Ciuclan L., Singer M.V., Dooley S. TGF-beta/Smad signaling in the injured liver. Zeitschrift Fur Gastroenterologie 2006, 44:57-66.
133. Ulloa L., Doody J., Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 1999, 397:710-713.
134. Mehal W.Z. Activation-induced cell death of hepatic stellate cells by the innate immune system. Gastroenterology 2006, 130:600-603.
135. Melhem A., Muhanna N., Bishara A., Alvarez C.E., Ilan Y., Bishara T., et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. Journal of Hepatology 2006, 45:60-71.
136. Radaeva S., Sun R., Jaruga B., Nguyen V.T., Tian Z.G., Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006, 130:435-452.
137. Jeong W.I., Park O., Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 2008, 134:248-258.
138. Worns M.A., Weinmann A., Schuchmann M., Galle P.R. Systemic therapies in hepatocellular carcinoma. Digestive Diseases 2009, 27:175-188.
139. Schutte K., Bornschein J., Malfertheiner P. Hepatocellular carcinoma: epidemiological trends and risk factors. Digestive Diseases 2009, 27:80-92.
140. Zhu A.X. Systemic treatment of hepatocellular carcinoma: dawn of a new era?. Annals of Surgical Oncology 2010, 17:1247-1256.
141. Komita H., Homma S., Saotome H., Zeniya M., Ohno T., Toda G. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8(+)T cells directly induces apoptosis of mouse hepatocellular carcinoma. Journal of Hepatology 2006, 45:662-672.
142. Matsui M., Machida S., Itani-Yohda T., Akatsuka T. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma. Journal of Gastroenterology and Hepatology 2002, 17:897-907.
143. Nagao M, Nakajima Y., Kanehiro H., Hisanaga M., Aomatsu Y., Ko S., et al. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology 2000, 32:491-500.